SUMMARYBackground: Cyclo-oxygenase-2-selective non-steroidal anti-inflammatory drugs are intended to preserve cyclooxygenase-1-mediated gastroprotection and platelet function, whilst inhibiting cyclo-oxygenase-2-mediated inflammation. Aim: To assess the gastrointestinal safety of the cyclooxygenase-2-selective inhibitor etoricoxib vs. nonselective non-steroidal anti-inflammatory drugs. Methods: Two randomized, double-blind, placebo-and active-controlled studies were performed: (i) daily faecal red blood cell loss was measured in 62 subjects receiving etoricoxib (120 mg once daily), ibuprofen (800 mg t.d.s.) or placebo for 28 days; (ii) the incidence of endoscopically detectable gastric ⁄ duodenal ulcers was determined in 742 osteoarthritis or rheumatoid arthritis

No abstract

No abstract

Methodology used to support changes to the Regulations for bottled water in the Food and Drugs Act of Canada, which include criteria for Pseudomonas aeruginosa (0 colony-forming units/100 mL of water), was used to assess the survival of P. aeruginosa in inoculated bottled water. The effects of P. aeruginosa on the survival of Salmonella spp. in bottled water were also investigated. The methodology used in the isolation included the use of hydrophobic grid membrane filters, a resuscitation step on tryptic soy agar, and selective plating on P. aeruginosa selective agar for P. aeruginosa and on xylose lysine desoxycholate agar for salmonellae. Pseudomonas aeruginosa and salmonellae proliferated and survived in inoculated water for up to 100 days or longer. Pseudomonas aeruginosa had a synergistic effect on the survival of salmonellae, enabling them to survive for more than 140 days in double distilled water.